Clinical Trials Logo

P53 Mutation clinical trials

View clinical trials related to P53 Mutation.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT04906031 Recruiting - Clinical trials for Acute Myeloid Leukemia

Sodium Stibogluconate in the MDS/AML With One of the 65 Defined p53 Mutations

Start date: June 1, 2020
Phase: Phase 2
Study type: Interventional

To evaluate the safety and effectiveness of Sodium Stibogluconate in the treatment of myelodysplastic syndrome/acute myeloid leukemia (MDS/AML) with p53 mutation from a defined list. The list includes 65 p53 mutations that were experimentally confirmed to be pharmacologically restored with tumor-suppressive function by antimonials.

NCT ID: NCT04159155 Recruiting - Clinical trials for Endometrial Carcinoma

A Study of Various Treatments in Serous or p53 Abnormal Endometrial Cancer

CAN-STAMP
Start date: November 17, 2020
Phase: Phase 2/Phase 3
Study type: Interventional

This is an umbrella, two-arm, multi-stage, phase II trial. The purpose of the trial in the early stage cohort is to determine if EBRT improves disease free survival (defined as the time from random assignment to disease recurrence or death from any cause) compared to vaginal brachytherapy after chemotherapy in women with serous or p53 aberrant endometrial cancer. The purpose of the trial in the advanced stage cohort is to determine if the maintenance with experimental treatment increases progression free survival, defined as the time from random assignment to disease progression or death from any cause.

NCT ID: NCT03855371 Recruiting - Aml Clinical Trials

Mutant p53-based Personalized Trial Using Decitabine and Arsenic Trioxide on AML/MDS

PANDA-T0
Start date: January 10, 2018
Phase: Phase 1
Study type: Interventional

TP53 mutation is commonly associated with poor cancer patient prognosis yet no mutant p53 (mp53)-targeting regimen was clinically established. Here the investigators try to evaluate the side effect and treatment potential of DAC+ATO in p53 mutated high-risk AML/MDS patients. About 200 AML/MDS patients will be sequenced for TP53 sequence before recruitment. The investigators estimated about 5 patients, based on the reported p53 mutation frequency in AML/MDS, will be p53-mutated. In the trial, the investigators will selectively recruit the mp53 AML/MDS patients that are predicted to respond to DAC+ATO regimen with highest chance (based on the relevant basic studies). The investigators designate mutant p53-based clinical trials as 'PANDA (P53 AND Arsenic)-Trials'.

NCT ID: NCT03611868 Recruiting - Melanoma Clinical Trials

A Study of APG-115 in Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors

Start date: August 29, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

Part 1 is the dose escalation of APG-115 in combination with label dose of pembrolizumab. Part 2 is phase II design of APG-115 at recommended phase 2 dose (RP2D) in combination with pembrolizumab.